News

For all media inquiries, please contact media@tempus.com

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

Tempus announced an extension of its data license agreement with Recursion Pharmaceuticals through November 2029, and a new agreement under which Tempus will license Recursion’s TxFM RNA foundation model.

Sep 21, 2026

Press Release

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-driven Healthcare Innovation

Tempus announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information, creating the first de-identified multimodal whole-genome sequencing dataset built around disease populations and patient outcomes.

Sep 11, 2026

Press Release

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

Tempus has been selected by ARPA-H to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure.

Sep 09, 2026

Press Release

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

CHICAGO, September 4, 2026 — Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.

Sep 04, 2026

Press Release

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead ECGs for signs associated with pulmonary hypertension.

Aug 24, 2026

Press Release

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

Tempus’ multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis.

Aug 04, 2026

Press Release

Tempus Reports Second Quarter 2026 Results

CHICAGO, July 30, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026.

Jul 30, 2026

Press Release

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Tempus AI, Inc. announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment.

Jul 22, 2026

Press Release

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth

Jul 20, 2026

Press Release

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

Findings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads

Jul 16, 2026

Press Release

‌
‌
‌